As described in the Leadership and Administration Core, an interdisciplinary group of senior leaders is available to interact with each other on a variety of substantive committees - two of which serve to evaluate developmental research studies and guide decision making on the use of stored specimens or the collection of prospective specimens needed to conduct these studies. In this section of the SPORE proposal we describe the allocation of SPORE resources to DRP projects. There are four kinds of SPORE resources: funding to support the research costs of developmental studies, access to stored specimens for use in developmental studies, access to a patient population with the potential to collect prospective specimens to support developmental studies, and data describing prior characterization of banked annotated specimens. In recognition of rapidly changing technology and new and novel applications of such technology for research, approximately $176,000 in total costs will be available per year in the Developmental Research Program (DRP) budget. Matching institutional funds from Fred Hutchinson Cancer Research Center (FHCRC) will be available at the discretion ofthe PI for outstanding ovarian SPORE developmental research projects that address SPORE priorities in risk assessment and early detection, immunotherapy, molecular signatures, and development of novel treatments of ovarian cancer (see FHCRC letter of institutional commitment). Through early detection we hope to improve outcomes significantly, because 1) currently available treatments are more effective in disease confined to the ovary, and 2) we will develop novel, relatively non-toxic treatments that will be particularly effective in early-stage disease. The tools of molecular biology, immunology and immunotherapy are emphasized in the translational research program. The POCRC is a community based, multidisciplinary, translational research program that involves clinicians, laboratory scientists and public health scientists from several research and medical institutions in the region. The broad based approach takes full advantage ofthe scientific expertise available locally and allows the pooling of clinical resources, thus facilitating population-based studies despite the low incidence of ovarian cancer. Applications will be solicited annually for use of these funds, and each application will be reviewed for its scientific merit and its resource needs including access to specimens. This section of the SPORE application outlines the POCRC's system for evaluation of developmental research study applications and progress. It also includes a summary report on previously funded or on-going projects, as well as several examples of projects that might be initiated next year if funding is available. Dr. Martin Mcintosh, program leader, will oversee this program and the Executive Committee will evaluate the progress ofthe funded developmental research studies. This program has, and will continue to be, flexible in nature and funding priorities will change according to scientific needs ofthe overall program. Exciting laboratory science with translational potential is a high priority. DRP applications should be designed to develop within a couple years into full-scale translational research projects suitable for a SPORE or ROI application. As collaboration between a laboratory, clinical and/or public health scientist greatly facilitates translational research, DRP projects are usually co-directed by an interdisciplinary team of two investigators. Inclusion of a POCRC/SPORE investigator as a co-director facilitates integration with SPORE themes and appropriate use of the SPORE core resources. Since 1999, the POCRC DRP has funded 29 developmental research proposals with approximately $1.5 million in total funding support. A total of 66 applications have been reviewed, for a funding rate of 44%. We will continue to use the current peer-review process to select new projects to be supported by SPORE resources, as it has been very successful.. SPORE funds have been awarded to highly meritorious applicants proposing studies that complement on-going POCRC projects and meet translational research criteria each year. Six of the DRP awards have led to new projects (Projects 4 and 5) or new roles in the next funding period for an investigator (Tewari, Swisher, Salazar, and Knudsen). DRP funds have been used to grow new scientific projects and project leaders in the current SPORE award and in this application, as can be seen in Table 1. The process that is in place will be used during the next funding period, as described below.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA083636-15
Application #
8523025
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
15
Fiscal Year
2013
Total Cost
$60,570
Indirect Cost
$18,078
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Wang, Yifan; Krais, John J; Bernhardy, Andrea J et al. (2016) RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance. J Clin Invest 126:3145-57
Norquist, Barbara M; Harrell, Maria I; Brady, Mark F et al. (2016) Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol 2:482-90
Yu-Rice, Yi; Edassery, Seby L; Urban, Nicole et al. (2016) Selenium Binding Protein 1 autoantibodies in ovarian disorders and ovarian cancer. Reproduction :
Yumul, Roma; Richter, Maximilian; Lu, Zhuo-Zhuang et al. (2016) Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor Models. Hum Gene Ther 27:325-37
Wang, Yifan; Bernhardy, Andrea J; Cruz, Cristina et al. (2016) The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Res 76:2778-90
Andersen, M Robyn; Thorpe, Jason; Buist, Diana S M et al. (2016) Cancer Risk Awareness and Concern among Women with a Family History of Breast or Ovarian Cancer. Behav Med 42:18-28
Buas, Matthew F; Gu, Haiwei; Djukovic, Danijel et al. (2016) Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors. Gynecol Oncol 140:138-44
Elias, Kevin M; Emori, Megan M; Westerling, Thomas et al. (2016) Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors. JCI Insight 1:
Gregory, Mark T; Bertout, Jessica A; Ericson, Nolan G et al. (2016) Targeted single molecule mutation detection with massively parallel sequencing. Nucleic Acids Res 44:e22
Bernards, Sarah S; Norquist, Barbara M; Harrell, Maria I et al. (2016) Genetic characterization of early onset ovarian carcinoma. Gynecol Oncol 140:221-5

Showing the most recent 10 out of 167 publications